Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Long-term clinical outcome assessments in patients with tenosynovial giant cell tumor treated with vimseltinib: 1-year results from the MOTION phase 3 trial.
Vivek A. Bhadri, Hans Gelderblom, Silvia Stacchiotti, Sebastian Bauer, Andrew J. Wagner, Michiel A. J. van de Sande, Nicholas M. Bernthal, Antonio López–Pousa, Albiruni Ryan Abdul Razak, Antoîne Italiano, Mahbubl Ahmed, Axel Le Cesne, Christopher Tait, Amanda Saunders, Nicholas Zeringo, B. Harrow, Maitreyi G. Sharma, Matthew L. Sherman, Jean Yves Blay, William D. Tap (2025). Long-term clinical outcome assessments in patients with tenosynovial giant cell tumor treated with vimseltinib: 1-year results from the MOTION phase 3 trial.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.11558.
Article47 days ago2694P Long-term efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): 2-year results from the MOTION phase III trial
Sebastian Bauer, Vivek A. Bhadri, H. Gelderblom, S. Stacchiotti, Andrew J. Wagner, Meike van de Sande, Nicholas M. Bernthal, Albiruni Ryan Abdul Razak, A. Italiano, M. Ahmed, A. Le Cesne, Christopher Tait, Fiona Zarins, N. Zeringo, B. Harrow, Manu Sharma, M.L. Sherman, Jean Yves Blay, W.D. Tap (2025). 2694P Long-term efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): 2-year results from the MOTION phase III trial. , 36, DOI: https://doi.org/10.1016/j.annonc.2025.08.3305.
Article47 days agoEfficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial.
William D. Tap, Vivek A. Bhadri, Silvia Stacchiotti, Sebastian Bauer, Andrew J. Wagner, Michiel A. J. van de Sande, Nicholas M. Bernthal, Antonio López–Pousa, Albiruni Ryan Abdul Razak, Antoîne Italiano, Mahbubl Ahmed, Axel Le Cesne, Christopher Tait, Fiona Zarins, B. Harrow, Maitreyi G. Sharma, Rodrigo Ruiz‐Soto, Matthew L. Sherman, Jean Yves Blay, Hans Gelderblom (2024). Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial.. , 42(16_suppl), DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.11500.
Article47 days agoLBA78 Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): One-year follow-up from the MOTION phase III trial
H. Gelderblom, Vivek A. Bhadri, S. Stacchiotti, Sebastian Bauer, Andrew J. Wagner, Meike van de Sande, Nicholas M. Bernthal, Albiruni Ryan Abdul Razak, A. Italiano, M. Ahmed, Axel Le Cesne, Christopher Tait, A. Saunders, B. Harrow, Manu Sharma, R. Ruiz-Soto, M.L. Sherman, Jean Yves Blay, W.D. Tap (2024). LBA78 Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): One-year follow-up from the MOTION phase III trial. , 35, DOI: https://doi.org/10.1016/j.annonc.2024.08.2321.
Article47 days agoVimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Hans Gelderblom, Vivek A. Bhadri, Silvia Stacchiotti, Sebastian Bauer, Andrew J. Wagner, Michiel A. J. van de Sande, Nicholas M. Bernthal, Antonio López–Pousa, Albiruni Abdul Razak, Antoîne Italiano, Mahbubl Ahmed, Axel Le Cesne, Gabriel Tinoco, Kjetil Boye, Javier Martín‐Broto, Emanuela Palmerini, Salvatore Tafuto, Sarah Pratap, Benjamin Powers, Peter Reichardt, Antonio Casado, Piotr Rutkowski, Christopher Tait, Fiona Zarins, B. Harrow, Maitreyi G. Sharma, Rodrigo Ruiz‐Soto, Matthew L. Sherman, Jean Yves Blay, William D. Tap, Herbert H. Loong, Antonella Brunello, Andreas H. Krieg, Mark Algulnik, Richard F. Riedel, Scott H. Okuno, Elizabeth T. Loggers, Thierry Alcindor, Virginia Ferraresi, César Serrano, R. Lor Randall, Breelyn A. Wilky, Vinod Ravi (2024). Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. , 403(10445), DOI: https://doi.org/10.1016/s0140-6736(24)00885-7.
Article47 days ago